Antiviral activity seen at all dose levels tested

PEG-Interferon lambda is a Targeted Type 3 interferon in development for Hepatitis C

King Pharmaceuticals, Inc. (KG) reported third quarter earnings of 29 cents per share, beating the Zacks Consensus Estimate by 2 cents. Despite revenues increasing 19.3% from the year-ago period, earnings declined 25.6% from the year-ago quarter mainly due to higher operating expenses. Total revenues came in at $463.3 million. The primary growth drivers were the Animal [...]

($KG) King Pharmaceuticals Beats Consensus, but Earnings Down

 

{tiny;BIOC;3} BioClinica, Inc. (NASDAQ: BIOC) will release its financial results for the third quarter ended September 30, 2009 on Wednesday, November 4, 2009.

Management of BioClinica, Inc. will host a conference call on the same day at 11 a.m. EST. Those who wish to participate in the conference call may telephone 888-335-6674 from the U.S.; international callers may telephone 973-321-1100, approximately 15 minutes before the call. The conference ID# for both numbers is 36541392. There will be a simultaneous webcast on www.bioclinica.com. A digital replay will be available by telephone approximately two hours after the call’s completion for two weeks, and may be accessed by dialing 800-642-1687 from the U.S. or 706-645-9291 for international callers, conference ID# 36541392. The replay will also be on the website under “Investor Relations” at www.bioclinica.com for two weeks.

{tiny;MDVN;3} Medivation, Inc. (Nasdaq:MDVN) today announced that it will host a teleconference and webcast with management to discuss third quarter 2009 financial results and provide a general business update on Wednesday, November 4, 2009, at 4:30 p.m. Eastern Time. A press release for the third quarter ended September 30, 2009 will be released after markets close on November 4, 2009.

Interested parties may call 877-874-1563 from the U.S. or +1-719-325-4891 internationally. Individuals interested in listening to the live call via webcast may do so by visiting http://www.medivation.com. A replay of the webcast will be available on the Company's website for 30 days.

 

{tiny;GNVC;3} GenVec, Inc. (Nasdaq: GNVC) announced that it will release financial results for the third quarter ended September 30, 2009 on Thursday, November 5, 2009 after market close. GenVec will hold a conference call at 10:00 a.m. EST on Friday, November 6, 2009 to discuss the company's third quarter results.

To listen to the live conference call, please dial 888-679-8040 (U.S. or Canada) or 617-213-4851 (international) and use access code 35178683. Participants may pre-register for the call anytime at:

https://www.theconferencingservice.com/prereg/key.process?key=PPCBK3H6R.

Pre-registrants will be issued a PIN number to use when dialing into the live call, which will provide quick access to the conference. An audio replay of the conference call will be available starting at 1:00 p.m. on November 6, 2009 through November 12, 2009. To listen to the audio replay, dial 888-286-8010 (U.S. or Canada) or 617-801-6888 (international) and use access code 28987203.

{tiny;RIGL;3} Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that James M. Gower, chairman and chief executive officer, and Raul R. Rodriguez, executive vice president and chief operating officer of Rigel, will present at two separate investor conferences in November. Details of each conference are as follows: Oppenheimer 20th Annual Healthcare Conference Waldorf Astoria, New York City, NY November 3, 2:10 p.m. EST Speaker: Raul R. Rodriguez Credit Suisse 18th Annual Healthcare Conference Arizona Biltmore Hotel, Phoenix, AZ November 11, 2:00 p.m. MST Speaker: James M. Gower

Both presentations will be webcast. To access the live webcast or the subsequent archived recording, log on to www.rigel.com. Please connect to Rigel's website several minutes prior to the start of the live webcast to ensure adequate time for any software download that may be necessary.

{tiny;HALO;3} Halozyme Therapeutics, Inc. (Nasdaq:HALO), a biopharmaceutical company developing and commercializing products targeting the extracellular matrix, today announced it plans to report third quarter 2009 financial results on Friday, November 6, 2009 before the open of the financial markets. The announcement will be followed by a conference call with the investment community at 8:00 a.m. PST (11:00 a.m. EST), which will be simultaneously broadcast over the Internet. Management will discuss the financial results and highlights for the third quarter 2009 and provide a product pipeline update.

To participate by telephone please dial 888-256-9044 for domestic callers or 706-643-5585 for international callers and provide the conference ID # 37881291. Those interested in listening to the conference call live via the Internet may do so by visiting the Investor Relations section of the company’s Web site at www.halozyme.com. Shortly after the call an audio replay will be available on Halozyme’s Web site for seven days. A telephone replay will be available by dialing 800-642-1687 from the U.S., or 706-645-9291 for international callers.

Halozyme management team members will also be presenting at upcoming investor conferences.

Oppenheimer 20th Annual Healthcare Conference, November 4, 2009, 3:20 p.m. EST, New York City Lazard Capital Markets 6th Annual Healthcare Conference, November 18, 2009, 11:30 a.m. EST, New York City

To listen to the audio webcast of the presentations live or after the event, please visit the company’s Web site at www.halozyme.com. Replays will be available for 30 days after the presentations.

{tiny;ZGEN;3} ZymoGenetics, Inc. (NASDAQ:ZGEN) announced today that Stephen W. Zaruby, President of ZymoGenetics, will provide an update on company activities at the Oppenheimer 20th Annual Healthcare Conference in New York City on Wednesday, November 4, 2009 at 10:50 a.m. Eastern Time.

A live webcast of the presentation can be accessed by going to: www.zymogenetics.com. The webcast will be archived for 30 days.

 

 

 

{tiny;SSRX;3} 3SBio Inc. (Nasdaq: SSRX) ("3SBio" or "the Company"), a leading China-based biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products, today announced that it will release financial results for the third quarter ended September 30, 2009 after the US market closes on Thursday, November 12, 2009.

Following the earnings announcement, 3SBio's senior management will host a conference call at 5:00 am (Pacific) / 8:00 am (Eastern) / 9:00 pm (Beijing/Hong Kong) on Friday, November 13, 2009 to discuss its 2009 third quarter financial results and recent business activity. The conference call may be accessed using the dial-in numbers below:

Conference ID: 38479039 Local dial-in: China - landline 800-819-0121 China - mobile 400-620-8038 International toll-free dial-in: Hong Kong 800930346 United Kingdom 080-8234-6646 United States 1-866-519-4004 International toll dial-in: 65-6735-7955 Replay-Conference ID: 38479039

A telephone replay will be available two hours after the call until November 20, 2009, at:

International dial-in: +61-2-8235-5000 United States dial-in: 1-866-214-5335

Webcast

A live webcast of the conference will be available on the investor relations page of 3SBio's website at http://bbs.3sbio.com/en/News/xinvestors.aspx and at http://tinyurl.com/yf93ntk . A replay of the webcast will be available within one hour after the conclusion of the call.

{tiny;OSIP;3} OSI Pharmaceuticals, Inc. (NASDAQ: OSIP) announced today that OSI Management will present at the Oppenheimer Healthcare Conference in New York, NY on Tuesday, November 3, 2009 at 3:20pm (Eastern Time) and will provide an overview on the Company’s product portfolio and business developments.

The presentation will be webcast live and may be accessed by visiting OSI’s website at www.osip.com. A replay of the webcast will also be available on the Company’s website until November 17, 2009.

 

 

{tiny;CPIX;3} Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX) announced today that it will report third quarter 2009 financial results before the market opens on Tuesday, November 10, 2009.A conference call and live Internet webcast will be held on Tuesday, November 10, 2009 at 10:00 a.m. Eastern Time to discuss the results.

To participate on the call, please dial 888-417-8462 (for U.S. callers) or 719-457-2552 (for international callers).A rebroadcast of the teleconference will be available for one week and can be accessed by dialing 888-203-1112 (for U.S. callers) or 719-457-0820 (for international callers).The passcode for the rebroadcast is 9695498.The live webcast and rebroadcast can be accessed via Cumberland Pharmaceuticals' website at http://investor.shareholder.com/cpix/events.cfm.

{tiny;INHX;3} Inhibitex, Inc. (NASDAQ: INHX) announced today that it will host a conference call on Friday, November 6, 2009 at 9:00 a.m. EDT to review the Company’s financial results for the third quarter ended September 30, 2009 and provide an update on recent corporate developments.

The Company will issue a press release regarding its financial results on the same day, prior to the conference call.

Webcast Information:  To access the conference call, please dial 877-407-8033 (domestic) or 201-689-8033 (international). A replay of the call will be available from 11:00 a.m. EDT on November 6 until December 6, 2009 at midnight. To access the replay, please dial 877-660-6853 (domestic) or 201-612-7415 (international) and reference the account # 286 and the conference id # 336098. A live audio webcast of the call and the archived webcast will be available in the News and Events section of the Inhibitex website at http://www.inhibitex.com.

King Pharmaceuticals, Inc. (KG) reported third quarter earnings of 29 cents per share, beating the Zacks Consensus Estimate by 2 cents. Despite revenues increasing 19.3% from the year-ago period, earnings declined 25.6% from the year-ago quarter mainly due to higher operating expenses.

Total revenues came in at $463.3 million. The primary growth drivers were the Animal Health business, which came as a part of the Alpharma acquisition and an increase in sales of auto-injectors in the Meridian business.

King’s branded pharmaceuticals segment posted revenues of $283 million, down 6.3% from the prior-year period. While generic versions of Altace continued to impact the top-line, both Skelaxin and Thrombin-JMI sales continued to decline on a year-over-year basis.

Thrombin-JMI sales came in at $43 million, down 35.8%. We expect Thrombin-JMI sales to continue declining due to the tough competition being faced by the product from ZymoGenetics’ (ZGEN) Recothrom and Omrix Biopharmaceuticals’ (OMRI) Evithrom.

Meanwhile, Skelaxin, which posted sales of $102 million (down 7.3%), is facing stiff competition from Cephalon’s (CEPH) Amrix. Amrix’ once-daily dosing regime and low rate of somnolence should provide it with an edge over other muscle relaxants like Skelaxin.

King is also facing patent challenges for Skelaxin and generic competition could enter later this year/early next year if the company does not enter into settlement agreements with the generic companies. Avinza sales also declined 13.9% to $31 million.

Flector Patch, obtained through King’s acquisition of Alpharma, recorded $40 million in sales in the reported quarter. King is promoting the product aggressively in order to drive sales. Embeda, another product obtained through the Alpharma acquisition, posted sales of $11 million. Revenues from the Animal Health business were $96 million for the reported quarter.

King’s Meridian Auto-Injector business continued to perform well with sales coming in at $72 million, up 5.9%. The launch of the next generation EpiPen Auto-Injector should help drive sales going forward.

Operating expenses increased significantly ($334 million, up 33.4%) mainly due to a significant increase in SG&A spending. A major part of the increase could be due to the company’s commercialization efforts in support of the Embeda launch.

The U.S. Food and Drug Administration approval of Embeda, which was launched on September 21, 2009, is a major milestone for King. We expect investor focus to remain on the successful commercialization of Embeda and the re-submission of King’s new drug application (NDA) on Remoxy, an opioid which is being developed with Pain Therapeutics (PTIE).
Read the full analyst report on "KG"
Read the full analyst report on "CEPH"
Read the full analyst report on "ZGEN"
Read the full analyst report on "OMRI"
Read the full analyst report on "PTIE"
Zacks Investment Research

King Pharmaceuticals, Inc. (KG) reported third quarter earnings of 29 cents per share, beating the Zacks Consensus Estimate by 2 cents. Despite revenues increasing 19.3% from the year-ago period, earnings declined 25.6% from the year-ago quarter mainly due to higher operating expenses.[More...]

The last week of September 2007 and the Stocks you should care about